Japan is often approached as a “partner market.” Find a distributor, sign a deal, and let them handle commercialization.
That model can work but it comes with a fundamental trade-off: you give up the customer.
For companies with strong assets and long-term ambition, there is a different path—one that is increasingly viable in Japan today: building your own local presence and engaging the market directly.
The Strategic Advantage: Owning the Customer Relationship
In Japan, relationships are not transactional—they are built over time, grounded in trust, consistency, and local relevance.
When you operate through a third party, you are one step removed from:
- Physicians and KOLs
- Hospital systems
- Payers and policy influencers
- Real-world patient experience
That distance matters.
Without direct engagement, you miss:
- Unfiltered market feedback on your product’s positioning and usage
- Early signals on competitive threats or shifting treatment patterns
- The ability to adapt your strategy in real time
Over time, this creates a structural disadvantage. You are not truly in the market—you are observing it through someone else’s lens.
From Product Revenue to Market Equity
A distributor can generate sales.
A subsidiary builds equity.
When you establish your own presence in Japan, you are not just commercializing a product—you are building:
- A recognized brand among healthcare professionals
- Direct credibility with regulators and payers
- A platform for future launches
- Institutional knowledge that compounds over time
This is particularly important in Japan, where continuity and reputation carry significant weight. The value of these assets often exceeds the near-term efficiency gained through outsourcing.
Control Drives Better Decisions
Operating directly gives you control over:
- Positioning and messaging in a highly nuanced market
- Pricing and market access strategy
- Medical engagement and evidence generation
- Lifecycle management and indication expansion
In a market with regular price revisions and evolving reimbursement dynamics, this control is not just beneficial—it is critical.
“Japan Is Too Difficult” — Less True Than It Used to Be
Historically, companies avoided direct entry due to perceived barriers:
- Talent constraints
- Regulatory complexity
- Cultural and language differences
These challenges still exist—but they are increasingly manageable:
- Japan is more open to foreign companies than ever before
- Experienced local talent is available, particularly for compelling products
- Regulatory pathways are more transparent with early engagement
In reality, many of the risks associated with building a subsidiary are execution challenges not structural barriers.
When a Direct Model Makes Sense
Building your own subsidiary is not for every company. It becomes compelling when:
- You have a differentiated or high-value asset
- Japan is a strategic, not opportunistic, market
- You are willing to invest with a multi-year horizon
- Customer insight and lifecycle control are critical to success
In these situations, the question is not “Can we afford to build?”
It is often “Can we afford not to?”
A More Flexible Reality: Start Direct, Scale Smart
Direct entry does not mean building everything at once.
Many successful companies:
- Establish a small, focused local team
- Hold key functions (strategy, KOL engagement, market access) internally
- Selectively outsource execution where needed
This approach allows you to own the customer relationship from day one, while scaling infrastructure over time.
The Bottom Line
Japan rewards companies that commit.
If you rely entirely on partners, you may gain speed—but you limit your visibility, control, and long-term upside.
If you build your own presence, you gain something far more valuable:
- Direct insight
- Strategic control
- Enduring market equity
In a market like Japan, those advantages compound and ultimately define who wins.